A major challenge in HIV vaccine development is the identification of immunogens able to elicit broadly neutralizing antibodies (bNAbs). While remarkable progress has been made in the isolation and characterization of bNAbs, the epitopes they recognize appear to be poorly immunogenic. Thus, none of the candidate vaccines developed to date has induced satisfactory levels of neutralizing antibodies to the HIV envelope protein (Env). One approach to the problem of poor immunogenicity is to build vaccines based on envelope (env) genes retrieved from rare individuals termed elite neutralizers (ENs) who at one time possessed specific sequences that stimulated the formation of bNAbs. Env proteins selected from these individuals could possess uncom...
The CD4 binding site (CD4bs) of the HIV-1 envelope glycoprotein is susceptible to multiple lineages ...
The CD4 binding site (CD4bs) of the HIV-1 envelope glycoprotein is susceptible to multiple lineages ...
Summary: Broadly neutralizing antibodies (bnAbs) targeting the HIV envelope glycoprotein (Env) typic...
A major challenge in HIV vaccine development is the identification of immunogens able to elicit broa...
SummaryBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV envelope (Env) tri...
After over 35 years of research, a prophylactic HIV vaccine remains elusive. However, the discovery ...
International audienceBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV env...
Abstract Broadly neutralizing antibodies (bNAbs), able to prevent viral entry by diverse global viru...
Understanding how broadly neutralizing antibodies (bnAbs) to HIV envelope (Env) develop during natur...
International audienceUnderstanding how broadly neutralizing antibodies (bnAbs) to HIV envelope (Env...
Vaccination strategies aimed at maturing broadly neutralizing antibodies (bnAbs) from naïve precurso...
Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subty...
Broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV)-1 are rare in nat...
A steady increase in knowledge of the molecular and antigenic structure of the gp120 and gp41 HIV-1 ...
Broadly Neutralizing Antibodies (bNAbs) can bind and neutralize multiple strains of HIV-1 at evoluti...
The CD4 binding site (CD4bs) of the HIV-1 envelope glycoprotein is susceptible to multiple lineages ...
The CD4 binding site (CD4bs) of the HIV-1 envelope glycoprotein is susceptible to multiple lineages ...
Summary: Broadly neutralizing antibodies (bnAbs) targeting the HIV envelope glycoprotein (Env) typic...
A major challenge in HIV vaccine development is the identification of immunogens able to elicit broa...
SummaryBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV envelope (Env) tri...
After over 35 years of research, a prophylactic HIV vaccine remains elusive. However, the discovery ...
International audienceBroadly neutralizing antibodies (bnAbs) directed to the V2 apex of the HIV env...
Abstract Broadly neutralizing antibodies (bNAbs), able to prevent viral entry by diverse global viru...
Understanding how broadly neutralizing antibodies (bnAbs) to HIV envelope (Env) develop during natur...
International audienceUnderstanding how broadly neutralizing antibodies (bnAbs) to HIV envelope (Env...
Vaccination strategies aimed at maturing broadly neutralizing antibodies (bnAbs) from naïve precurso...
Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subty...
Broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV)-1 are rare in nat...
A steady increase in knowledge of the molecular and antigenic structure of the gp120 and gp41 HIV-1 ...
Broadly Neutralizing Antibodies (bNAbs) can bind and neutralize multiple strains of HIV-1 at evoluti...
The CD4 binding site (CD4bs) of the HIV-1 envelope glycoprotein is susceptible to multiple lineages ...
The CD4 binding site (CD4bs) of the HIV-1 envelope glycoprotein is susceptible to multiple lineages ...
Summary: Broadly neutralizing antibodies (bnAbs) targeting the HIV envelope glycoprotein (Env) typic...